Innoviva, Inc
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. Show More...
-
Website http://www.inva.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 19.57 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -1.16 -1.41 -0.2 -1.67 -1.5 -0.16 0.53 1.17 3.53 1.43 1.71 Dividends USD 0.5 0.75 Payout Ratio % * Shares Mil 72.0 82.0 91.0 102.0 112.0 115.0 123.0 120.0 113.0 113.0 113.0 Book Value Per Share * USD -0.28 -0.69 1.58 2.96 -1.66 -2.81 -3.39 -2.19 -1.1 2.64 3.74 Free Cash Flow Per Share * USD -1.05 -1.01 -1.43 -1.58 -3.05 -0.010 0.41 0.89 1.82 2.23 Return on Assets % -32.72 -39.1 -5.91 -32.52 -28.01 -3.97 14.83 35.95 86.3 24.71 27.42 Financial Leverage (Average) 2.38 2.28 3.57 2.31 2.08 Return on Equity % -54.55 -75.17 -444.65 67.35 66.55 Return on Invested Capital % -6.3 -35.47 -24.27 27.39 29.92 Interest Coverage -12.96 -18.15 -2.09 -17.26 -0.99 0.64 2.14 4.08 9.78 13.48 16.05 Current Ratio 7.9 5.38 8.71 5.72 18.33 15.89 9.88 5.77 34.92 80.29 166.87 Quick Ratio 7.75 5.3 8.33 5.55 18.25 15.83 9.84 5.75 34.77 80.11 166.58 Debt/Equity 1.11 0.96 2.49 1.2 0.99